Research

Revision Anterior Cruciate Ligament Reconstruction in Adolescents

IRB Number: 10122
(inactive trial)

Institutional Review Board, Hospital for Special Surgery

August 16, 2010

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

Frank A. Cordasco, MD, MS

Co-Investigators

Keith R. Reinhardt, MD
Sommer Hammoud, MD
Andrea Bowers, MD
David W. Altchek, MD
Answorth A. Allen, MD
Robert G. Marx, MD
Andrew D. Pearle, MD
Anil S. Ranawat, MD
Anne M. Kelly, MD
Beth E. Shubin Stein, MD
Bryan T. Kelly, MD

David M. Dines, MD
Joshua S. Dines, MD
Edward V. Craig, MD. MPH
Howard Anthony Rose, MD

Jo A. Hannafin, MD, PhD
John D. MacGillivray, MD
Michael J. Maynard, MD
Riley J. Williams III, MD
Russell F. Warren, MD
Sabrina M. Strickland, MD
Scott A. Rodeo, MD
Stephen Fealy, MD
Steve J. O’Brien, MD, MBA
Struan H. Coleman, MD, MPH
Thomas L. Wickiewicz, MD

Summary

Review of outcomes of revision ACL reconstruction in adolescent patients ages 12-18.

Inclusion/Exclusion Criteria

Review of outcomes of revision ACL reconstruction in adolescent patients ages 12-18.

Contact Information

Keith Reinhardt, MD
krr9009@gmail.com
646-678-4402



Request an Appointment